NCT05457946View on ClinicalTrials.gov

Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

1,438

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
DiphtheriaTetanusPertussisHepatitis BPoliomyelitisHaemophilus Influenzae Type B Infection
Interventions
BIOLOGICAL

LBVD (Hexavalent vaccine)

Injection within the muscle into the front area of the thigh

BIOLOGICAL

Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains)

Injection within the muscle into the front area of the thigh

Sponsors

Lead Sponsor

LG Chem
All Listed Sponsors
lead

LG Chem

INDUSTRY

NCT05457946 - Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series | Biotech Hunter | Biotech Hunter